Gal Cohen
Director/Board Member at SILVER CASTLE HOLDINGS LTD
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Wills | M | 67 | 7 years | |
| Yaron Meyer | M | 45 | 11 years | |
| Yechezkel Barenholz | M | 82 |
Ayana Pharma Ltd.
 Ayana Pharma Ltd. Pharmaceuticals: MajorHealth Technology Ayana Pharma Ltd. is an Israeli pharmaceutical company that specializes in developing liposomal therapeutics for cancer treatment. The company is based in Jerusalem, Israel. Ayana Pharma was founded in 2012 by Yechezkel Barenholz and Avraham Molcho, with Yechezkel Barenholz serving as the CEO since its inception. | 12 years |
| Philip Serlin | M | 63 | 15 years | |
| Smadar Nestor | F | - | 16 years | |
| Ella Sorani | M | 56 | 7 years | |
| Eitan Segal | M | 59 | 7 years | |
| Rami Dar | M | 67 | 2 years | |
| Gal Furer | M | 60 | 4 years | |
| Eliezer Mizroach | M | 51 | 2 years | |
| Raf Hofstein | M | 74 | 21 years | |
| Vickie R. Driver | M | 70 | 7 years | |
| Barbara-Jean Bormann-Kennedy | M | 65 | 11 years | |
| Sandra Panem | M | 77 | 10 years | |
| Shai S. Erlich | M | 58 |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 25 years |
| John Lacey | M | - | - | |
| Aharon Schwartz | M | 80 | 20 years | |
| Rami Beinish | M | 52 | 2 years | |
| Avraham Molcho | M | 66 | 14 years | |
| Tali Yaron Dalah | F | 46 | - | |
| Roni Solomon | F | - | 18 years | |
| Holly May | F | - | 2 years | |
| Liora Ettinger | M | 43 |
Ayana Pharma Ltd.
Ayana Pharma Ltd. Pharmaceuticals: MajorHealth Technology Ayana Pharma Ltd. is an Israeli pharmaceutical company that specializes in developing liposomal therapeutics for cancer treatment. The company is based in Jerusalem, Israel. Ayana Pharma was founded in 2012 by Yechezkel Barenholz and Avraham Molcho, with Yechezkel Barenholz serving as the CEO since its inception. | 6 years |
| Aviva Ben Moshe | F | 58 | 2 years | |
| Chen Munitz | M | 49 | 2 years | |
| Ilan Grinboim | M | 64 | 2 years | |
| Irit Gliko-Kabir | M | - | 7 years | |
| Asaf Aloni | M | - | - | |
| Barbara Diamant | F | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | - |
| Yossi Erenst | M | 58 | 18 years | |
| Keren David-Zarbiv | F | - | 11 years | |
| Mali Zeevi | F | 48 | 15 years | |
| Hagit Ashus | M | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 23 years |
| Zvi Ziv | M | 74 | 2 years | |
| Rami Skaliter | M | 66 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 29 years |
| Elena Feinstein | M | 65 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 26 years |
| Juliana Friedmann | F | 72 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 26 years |
| Smadar Manor | M | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | - |
| Toshihiro Toyoshima | M | 61 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 14 years |
| Eilon Asculai | M | - | 17 years | |
| Elizabeth C. Squiers | M | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 15 years |
| Sharon Klier | M | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | - |
| Dorit Kreiner | F | 52 | 2 years | |
| Liana Patt | M | - |
Ayana Pharma Ltd.
Ayana Pharma Ltd. Pharmaceuticals: MajorHealth Technology Ayana Pharma Ltd. is an Israeli pharmaceutical company that specializes in developing liposomal therapeutics for cancer treatment. The company is based in Jerusalem, Israel. Ayana Pharma was founded in 2012 by Yechezkel Barenholz and Avraham Molcho, with Yechezkel Barenholz serving as the CEO since its inception. | - |
| Tsipi Keren-Lehrer | F | - | 5 years | |
| Yoshitaka Kitao | M | 73 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 14 years |
| Ety Klinger | M | 62 | 10 years | |
| Tomer Natan | M | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 19 years |
| Teddy Ercegovic | M | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | - |
| Vidhya Gopalakrishnan | F | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | - |
| Yanir Aldouby | M | - |
Ayana Pharma Ltd.
Ayana Pharma Ltd. Pharmaceuticals: MajorHealth Technology Ayana Pharma Ltd. is an Israeli pharmaceutical company that specializes in developing liposomal therapeutics for cancer treatment. The company is based in Jerusalem, Israel. Ayana Pharma was founded in 2012 by Yechezkel Barenholz and Avraham Molcho, with Yechezkel Barenholz serving as the CEO since its inception. | 13 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Sharon Malka | F | 51 | - | |
| Marian Gorecki | M | 83 | 17 years | |
| Nissim Mashiach | M | 63 | - | |
| Sharon Kochan | F | 55 | - | |
| Meron Mann | M | 72 | 10 years | |
| Aharon Yaari | M | 72 | 2 years | |
| Ruben Krupik | M | 72 | 13 years | |
| Michael Anghel | M | 85 | 14 years | |
| Avri Havron | M | 76 | 3 years | |
| Sarit Firon | F | 58 | 3 years | |
| Gil Barzilay | M | - | - | |
| Nirit Freikorn | F | 50 | - | |
| Sigal Aviel | M | 60 | 1 years | |
| Assaf Segal | M | 51 | 6 years | |
| Carsten Henke | M | 58 | 6 years | |
| Roland Frösing | M | 64 | 7 years | |
| Yaron Shoham | M | - | 7 years | |
| Tami Rachmilewitz | M | 54 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 55 | 79.71% |
| United States | 14 | 20.29% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gal Cohen
- Personal Network
